13F GuideFiling Basics
What is SEC Form 13F? Ultimate Guide to Institutional Equity Filings
Learn how SEC Form 13F filings work, the $100M threshold, 45-day reporting lag, and how to track top hedge fund holdings.
AlphaSMO Research GuideRead Guide
CIK: 0001583977
Total reported value
$2.0B
$2.0B
35 檔
50.8%
The Q4 2025 SEC filing reveals that Cormorant Asset Management, LP held a total portfolio value of $2.0B, covering 35 public equity positions.
In Q4 2025, Cormorant Asset Management, LP adopted a defensive or profit-taking posture, trimming 22 positions and completely liquidating 7 holdings to manage risk exposure.
| # | Ticker | Issuer | Asset Subclass | Weight | Weight Change | Shares Change | 4Q Trend |
|---|---|---|---|---|---|---|---|
| 1 | PRAX | Praxis Precision Medicines I | Stock-Other | 12.95% | -3.35% | -5.00% | |
| 2 | BBOT | Bridgebio Oncology Therapeut | Stock-Other | 10.35% | -1.06% | — | |
| 3 | ABVX | Abivax Sa-adr | Stock-Other | 8.42% | +0.36% | -30.77% | |
| 4 | QQQ | Invesco Qqq Trust Series 1 | ETF-Tech | 7.10% | — | — | |
| 5 | EYPT | Eyepoint Inc | Stock-Other | 6.98% | -0.22% | -0.72% | |
| 6 | IWM | Ishares Russell 2000 ETF | ETF-Small Cap | 5.69% | — | — | |
| 7 | XBI | Ss Spdr S&p Biotech ETF | ETF-Tech | 5.64% | — | — | |
| 8 | RAPP | Rapport Therapeutics Inc | Stock-Other | 4.25% | +1.02% | -5.17% | |
| 9 | BBIO | Bridgebio Pharma Inc | Stock-Healthcare | 4.24% | -1.07% | -14.29% | |
| 10 | DRUG | Bright Minds Biosciences Inc | Stock-Other | 3.82% | -0.64% | — | |
| 11 | EWTX | Edgewise Therapeutics Inc | Stock-Other | 3.77% | +0.07% | -18.08% | |
| 12 | OLMA | Olema Pharmaceuticals Inc | Stock-Other | 3.18% | -1.92% | — | |
| 13 | MLTX | Moonlake Immunotherapeutics | Stock-Other | 2.65% | -0.99% | +118.41% | |
| 14 | INSM | Insmed Inc | Stock-Healthcare | 2.21% | -1.15% | -36.05% | |
| 15 | ✓ | Engene Holdings Inc | Stock-Other | 1.67% | — | +72.15% | |
| 16 | ALMS | Alumis Inc | Stock-Other | 1.64% | +0.37% | +69.30% | |
| 17 | MBX | Mbx Biosciences Inc | Stock-Other | 1.63% | -0.12% | -8.57% | |
| 18 | NAMS | NewAmsterdam Pharma Company N.V. | Stock-Other | 1.62% | -0.66% | -54.02% | |
| 19 | 260 | Centessa Pharmaceuticals-adr | Stock-Other | 1.53% | -2.09% | EXIT | |
| 20 | PHVS | Pharvaris N.V. | Stock-Other | 1.39% | -0.09% | -20.55% | |
| 21 | BIOA | Bioage Labs Inc | Stock-Other | 1.25% | +0.46% | -4.67% | |
| 22 | ASND | Ascendis Pharma A/S | Stock-Other | 0.99% | -1.09% | EXIT | |
| 23 | TARS | Tarsus Pharmaceuticals Inc | Stock-Other | 0.95% | -0.47% | -16.67% | |
| 24 | CRBP | Corbus Pharmaceuticals Holdi | Stock-Other | 0.88% | +0.02% | -1.26% | |
| 25 | GHRS | GH Research PLC | Stock-Other | 0.76% | — | -32.17% | |
| 26 | ORKA | Oruka Therapeutics Inc | Stock-Other | 0.75% | +1.29% | — | |
| 27 | ARQT | Arcutis Biotherapeutics Inc | Stock-Other | 0.67% | -0.29% | -35.48% | |
| 28 | CRNX | Crinetics Pharmaceuticals In | Stock-Other | 0.65% | -0.22% | -25.00% | |
| 29 | AXSM | Axsome Therapeutics Inc | Stock-Healthcare | 0.63% | -0.42% | EXIT | |
| 30 | CABA | Cabaletta Bio Inc | Stock-Other | 0.45% | +0.06% | -12.00% | |
| 31 | JANX | Janux Therapeutics Inc | Stock-Other | 0.41% | — | -23.53% | |
| 32 | COGT | Cogent Biosciences Inc | Stock-Other | 0.37% | -0.19% | — | |
| 33 | PCVX | Vaxcyte Inc | Stock-Other | 0.27% | -0.14% | -28.57% | |
| 34 | AMLX | Amylyx Pharmaceuticals Inc | Stock-Other | 0.22% | -0.06% | -20.00% | |
| 35 | BHVN | Biohaven Ltd. | Stock-Other | 0.01% | +1.24% | — |
| # | Ticker | Issuer | Weight Change | Shares Change | Action |
|---|---|---|---|---|---|
| 1 | PRAX | Praxis Precision Medicines I | +9.3% | -5.00% | Trim |
| 2 | MLTX | Moonlake Immunotherapeutics | +1.7% | +118.41% | Add |
| 3 | ALMS | Alumis Inc | +1.1% | +69.30% | Add |
| 4 | ✓ | Engene Holdings Inc | +0.6% | +72.15% | Add |
| 5 | BIOA | Bioage Labs Inc | +0.4% | -4.67% | Trim |
| 6 | MBX | Mbx Biosciences Inc | +0.2% | -8.57% | Trim |
| 7 | ORKA | Oruka Therapeutics Inc | 0% | — | Unchanged |
| 8 | BHVN | Biohaven Ltd. | — | — | Unchanged |
| 9 | PCVX | Vaxcyte Inc | -0.2% | -28.57% | Trim |
| 10 | AXSM | Axsome Therapeutics Inc | -0.2% | -25.00% | Trim |
| 11 | AMLX | Amylyx Pharmaceuticals Inc | -0.3% | -20.00% | Trim |
| 12 | TARS | Tarsus Pharmaceuticals Inc | -0.3% | -16.67% | Trim |
| 13 | ARQT | Arcutis Biotherapeutics Inc | -0.3% | -35.48% | Trim |
| 14 | CABA | Cabaletta Bio Inc | -0.4% | -12.00% | Trim |
| 15 | CRNX | Crinetics Pharmaceuticals In | -0.5% | -25.00% | Trim |
| 16 | DRUG | Bright Minds Biosciences Inc | -0.6% | — | Unchanged |
| 17 | EWTX | Edgewise Therapeutics Inc | -0.7% | -18.08% | Trim |
| 18 | BBIO | Bridgebio Pharma Inc | -0.8% | -14.29% | Trim |
| 19 | PHVS | Pharvaris N.V. | -1% | -20.55% | Trim |
| 20 | JANX | Janux Therapeutics Inc | -1% | -23.53% | Trim |
| 21 | GHRS | GH Research PLC | -1.1% | -32.17% | Trim |
| 22 | CRBP | Corbus Pharmaceuticals Holdi | -1.2% | -1.26% | Trim |
| 23 | EYPT | Eyepoint Inc | -1.2% | -0.72% | Trim |
| 24 | 260 | Centessa Pharmaceuticals-adr | -1.7% | -31.17% | Trim |
| 25 | INSM | Insmed Inc | -2.1% | -36.05% | Trim |
| 26 | RAPP | Rapport Therapeutics Inc | -2.3% | -5.17% | Trim |
| 27 | NAMS | NewAmsterdam Pharma Company N.V. | -2.7% | -54.02% | Trim |
| 28 | ABVX | Abivax Sa-adr | -3% | -30.77% | Trim |
| 29 | BBOT | Bridgebio Oncology Therapeut | -3.9% | — | Unchanged |
| 30 | QQQ | Invesco Qqq Trust Series 1 | — | NEW | New buy |
| 31 | IWM | Ishares Russell 2000 ETF | — | NEW | New buy |
| 32 | XBI | Ss Spdr S&p Biotech ETF | — | NEW | New buy |
| 33 | OLMA | Olema Pharmaceuticals Inc | — | NEW | New buy |
| 34 | ACLXGBX | Arcellx Inc | — | EXIT | Sold out |
| 35 | CGON | Cg Oncology Inc | — | EXIT | Sold out |
| 36 | KRRO | Korro Bio Inc | — | EXIT | Sold out |
| 37 | ASND | Ascendis Pharma A/S | — | NEW | New buy |
| 38 | ✓ | — | EXIT | Sold out | |
| 39 | RNAGBP | Avidity Biosciences Inc | — | EXIT | Sold out |
| 40 | COGT | Cogent Biosciences Inc | — | NEW | New buy |
| 41 | BMEA | Biomea Fusion Inc | — | EXIT | Sold out |
| 42 | ELVN | Enliven Therapeutics Inc | — | EXIT | Sold out |
According to official SEC Form 13F filings, Cormorant Asset Management, LP reported a total U.S. public equity portfolio value of $2.0B across 35 disclosed positions in Q4 2025.
Expert Analysis & Guides for Tracking Wall Street Smart Money Movements
Learn how SEC Form 13F filings work, the $100M threshold, 45-day reporting lag, and how to track top hedge fund holdings.
In terms of portfolio concentration, the top 5 core holdings (including PRAX, BBOT, ABVX) accounted for 50.8% of total reported equity market value during Q4 2025.
Top New Position Initiated
QQQ
市值: $153.6M
Top Position Liquidated / Trimmed
ACLXGBX
前期市值: $63.6M
During Q4 2025, Cormorant Asset Management, LP's top holdings by market value included PRAX (12.9%)、BBOT (10.3%)、ABVX (8.4%). The largest single position, PRAX, represented 12.9% of total portfolio value.
In Q4 2025, Cormorant Asset Management, LP made 38 total portfolio adjustments, initiating 6 new buys, adding to 3 positions, trimming 22 holdings, and fully liquidating 7 stocks.
All holding records on this page are fetched directly from the U.S. Securities and Exchange Commission (SEC) EDGAR system (Form 13F-HR). AlphaSMO parses CUSIP identifiers and formats data into Schema.org-compliant datasets.
Understand SEC Form 4 insider disclosures for corporate officers, directors, and 10% owners to track executive transactions.
Understand Rule 144 restricted stock sale notices to spot planned insider liquidations before market sell pressure arrives.
Explore the 5% beneficial ownership threshold, 13D vs 13G filing differences, and recent SEC accelerated deadline rules.
Best practices for analyzing 13F quarterly changes without getting misled by stock splits, options, or market valuation drift.
Learn how AlphaSMO's flagship signal detects high-conviction stocks where 13F hedge funds and corporate insiders buy at the same time.